David A Scheinberg Selected Research

lintuzumab

1/2022	Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.
11/2010	Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.
6/2003	Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
8/2002	Targeted alpha particle immunotherapy for myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David A Scheinberg Research Topics

Disease

81	Neoplasms (Cancer) 01/2022 - 03/2002
20	Leukemia 01/2022 - 03/2002
10	Wilms Tumor (Wilm's Tumor) 01/2018 - 01/2003
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 06/2003
6	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 05/2002
6	Lymphoma (Lymphomas) 01/2020 - 01/2005
4	Breast Neoplasms (Breast Cancer) 01/2021 - 07/2004
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 09/2009 - 02/2004
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022 - 01/2017
3	Inflammation (Inflammations) 01/2018 - 09/2005
3	Malignant Mesothelioma 12/2017 - 08/2007
3	Myeloid Leukemia (Leukemia, Myelocytic) 01/2012 - 08/2002
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/2009 - 04/2003
2	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 01/2004
2	Testicular Neoplasms (Testicular Cancer) 01/2022 - 06/2017
2	Ovarian Neoplasms (Ovarian Cancer) 05/2021 - 08/2003
2	Melanoma (Melanoma, Malignant) 08/2020 - 06/2017
2	Neuroblastoma 01/2020 - 10/2004
2	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 08/2011
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2017 - 11/2016
2	Glioblastoma (Glioblastoma Multiforme) 11/2016 - 10/2016
2	Philadelphia Chromosome 05/2014 - 02/2004
2	Mesothelioma 10/2010 - 08/2007
2	Hypersensitivity (Allergy) 07/2010 - 02/2004
2	Graft vs Host Disease (Graft-Versus-Host Disease) 06/2010 - 03/2006
2	Residual Neoplasm 09/2009 - 03/2007
2	Prostatic Neoplasms (Prostate Cancer) 10/2008 - 10/2004
2	Carcinoma (Carcinomatosis) 03/2007 - 08/2003
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2004 - 08/2002
1	Ascites 05/2021

Drug/Important Bio-Agent (IBA)

23	Peptides (Polypeptides)IBA 01/2022 - 02/2004
21	AntigensIBA 01/2022 - 01/2003
16	AntibodiesIBA 01/2022 - 03/2002
15	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2003
13	Monoclonal AntibodiesIBA 01/2016 - 03/2002
11	EpitopesIBA 01/2022 - 08/2007
11	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 07/2013
9	LigandsIBA 01/2022 - 12/2008
9	Radioisotopes (Radionuclides)IBA 08/2020 - 03/2002
9	VaccinesIBA 01/2018 - 01/2003
7	HLA-A Antigens (HLA-A)IBA 01/2022 - 08/2014
7	Carbon Nanotubes (Carbon Nanotube)IBA 01/2018 - 07/2007
7	Protein Subunit VaccinesIBA 01/2018 - 02/2004
7	Oncogene Proteins (Oncogene Protein)IBA 01/2017 - 10/2006
6	Pharmaceutical PreparationsIBA 01/2022 - 03/2007
6	Histocompatibility Antigens Class IIBA 12/2019 - 01/2008
6	WT1 ProteinsIBA 01/2018 - 01/2003
5	Immunoglobulin G (IgG)IBA 12/2021 - 10/2004
5	Actinium-225IBA 08/2020 - 08/2003
5	Transcription Factors (Transcription Factor)IBA 08/2014 - 08/2007
5	IsotopesIBA 10/2011 - 08/2002
4	lintuzumabIBA 01/2022 - 08/2002
4	EnzymesIBA 01/2022 - 02/2004
4	cadherin 5IBA 11/2010 - 03/2007
4	Imatinib Mesylate (Gleevec)FDA Link 09/2009 - 02/2004
3	Chimeric Antigen ReceptorsIBA 01/2022 - 01/2020
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 01/2017
3	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2021 - 10/2010
3	Antineoplastic Agents (Antineoplastics)IBA 08/2020 - 10/2008
3	DNA (Deoxyribonucleic Acid)IBA 09/2012 - 01/2005
3	Interferon-gamma (Interferon, gamma)IBA 10/2010 - 02/2004
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2009 - 04/2003
3	Immunoconjugates (Immunoconjugate)IBA 05/2006 - 08/2003
2	RNA (Ribonucleic Acid)IBA 05/2021 - 01/2018
2	HLA Antigens (Human Leukocyte Antigens)IBA 05/2021 - 12/2019
2	Phosphotransferases (Kinase)IBA 12/2019 - 11/2016
2	PanobinostatIBA 11/2018 - 01/2017
2	ibrutinibIBA 11/2018 - 01/2017
2	Messenger RNA (mRNA)IBA 01/2017 - 11/2016
2	Therapeutic UsesIBA 10/2016 - 09/2007
2	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 08/2014 - 05/2012
2	OligonucleotidesIBA 10/2013 - 12/2008
2	Liposomes (Liposome)IBA 12/2010 - 02/2004
2	E4G10 antibodyIBA 11/2010 - 10/2010
2	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2010 - 08/2002
2	Rituximab (Mabthera)FDA Link 02/2009 - 04/2006
2	Prostate-Specific Antigen (Semenogelase)IBA 10/2008 - 03/2007
2	Pentostatin (Nipent)FDA LinkGeneric 04/2006 - 04/2003
2	purineIBA 04/2006 - 04/2003
2	Alkylating AgentsIBA 04/2006 - 04/2003
2	actinoninIBA 10/2004 - 12/2003
2	Trastuzumab (Herceptin)FDA Link 07/2004 - 08/2003
1	ProdrugsIBA 01/2022
1	Enhancer of Zeste Homolog 2 ProteinIBA 01/2022
1	E2F Transcription FactorsIBA 01/2022
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2022
1	PhosphopeptidesIBA 01/2022
1	GTP-Binding Proteins (G-Protein)IBA 01/2022
1	Drug CombinationsIBA 01/2022
1	abemaciclibIBA 01/2021
1	palbociclibIBA 01/2021
1	Silicon Dioxide (Silica)FDA LinkGeneric 08/2020
1	Type 1 Melanocortin ReceptorIBA 08/2020
1	Melanocyte-Stimulating Hormones (MSH)IBA 08/2020

Therapy/Procedure

34	Therapeutics 01/2022 - 05/2002
17	Immunotherapy 01/2022 - 08/2002
7	Radioimmunotherapy 01/2020 - 03/2002
3	Radiotherapy 10/2010 - 03/2007
3	Transplantation 06/2010 - 02/2004
2	Drug Therapy (Chemotherapy) 11/2010 - 03/2007